Recent strategies in the development of new human cytomegalovirus inhibitors

被引：20

作者：

Martinez, A ^{[1
]}

Castro, A ^{[1
]}

Gil, C ^{[1
]}

Perez, C ^{[1
]}

机构：

[1] CSIC, Inst Quim Med, E-28006 Madrid, Spain

来源：

MEDICINAL RESEARCH REVIEWS | 2001年 / 21卷 / 03期

关键词：

HCMV inhibitors; HCMV protease; opportunistic infection; immunocompromised patients;

D O I：

10.1002/med.1008

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Human cytomegalovirus (HCMV) is one of the most common opportunistic infections in immunucompromised individuals, such as AIDS patients and organ transplant recipients, and is the most frequent congenital viral infection in humans. Despite a reduction of the incidence of AIDS-related opportunistic infections in patients under highly active antiretroviral treatment, attention should be paid to the HCMV risk factor in these individuals. Furthermore, HCMV may have an important role in atherosclerosis. Existing antiviral treatments for the HCMV infection suffer from poor bioavailability, toxicity, and limited effectiveness, mainly due to the development of drug resistance. Fortunately there are novel and potentially very effective new compounds undergoing pre-clinical and clinical evaluation. This review provides an overview in the last five years of new HCMV inhibitors (chemical structures, SAR and new mechanisms of action) with the aim to provide neu clues for the development of the future drugs against this opportunistic virus. (C) 2001 John Wiley & Sons. Inc.

引用

收藏

页码：227 / 244

页数：18

相关论文

共 130 条

[1] Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture [J].

Abood, NA ;

Schretzman, LA ;

Flynn, DL ;

Houseman, KA ;

Wittwer, AJ ;

Dilworth, VM ;

Hippenmeyer, PJ ;

Holwerda, BC .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (16) :2105-2108

[2] Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir [J].

Abraham, B ;

Lastere, S ;

Reynes, J ;

Bibollet-Ruche, F ;

Vidal, N ;

Segondy, M .

JOURNAL OF CLINICAL VIROLOGY, 1999, 13 (03) :141-148

[3]

Armas JCG, 1996, J VIROL, V70, P7921

[4]

Augustynowicz Ewa, 1998, Acta Microbiologica Polonica, V47, P373

[5] Coinfection of the immunocompromised but not the immunocompetent host by multiple human cytomegalovirus strains [J].

Baldanti, F ;

Sarasini, A ;

Furione, M ;

Gatti, M ;

Comolli, G ;

Revello, MG ;

Gerna, G .

ARCHIVES OF VIROLOGY, 1998, 143 (09) :1701-1709

[6] Antiviral properties of a series of 1,6-naphthyridine and 7,8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus [J].

Bedard, J ;

May, S ;

L'Heureux, L ;

Stamminger, T ;

Copsey, A ;

Drach, J ;

Huffman, J ;

Chan, L ;

Jin, HL ;

Rando, RF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :929-937

[7] Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir [J].

Bedard, J ;

May, S ;

Lis, M ;

Tryphonas, L ;

Drach, J ;

Huffman, J ;

Sidwell, R ;

Chan, L ;

Bowlin, T ;

Rando, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :557-567

[8] A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors [J].

Bedard, J ;

May, S ;

Barbeau, D ;

Yuen, L ;

Rando, RF ;

Bowlin, TL .

ANTIVIRAL RESEARCH, 1999, 41 (01) :35-43

[9] Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice [J].

Berencsi, K ;

Endresz, V ;

Klurfeld, D ;

Kari, L ;

Kritchevsky, D ;

Gonczol, E .

CELL ADHESION AND COMMUNICATION, 1998, 5 (01) :39-+

[10] Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors [J].

Bonneau, PR ;

GrandMaitre, C ;

Greenwood, DJ ;

Lagace, L ;

LaPlante, SR ;

Massariol, MJ ;

Ogilvie, WW ;

OMeara, JA ;

Kawai, SH .

BIOCHEMISTRY, 1997, 36 (41) :12644-12652

← 1 2 3 4 5 6 7 8 9 10 →